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Background. Cryptococcal meningitis (CM) is a leading cause of death in individuals infected with human im-
munodeﬁciency virus (HIV). Identifying factors associated with mortality informs strategies to improve outcomes.
Methods. Five hundred one patients with HIV-associated CM were followed prospectively for 10 weeks during
trials in Thailand, Uganda, Malawi, and South Africa. South African patients (n = 266) were followed for 1 year.
Similar inclusion/exclusion criteria were applied at all sites. Logistic regression identiﬁed baseline variables indepen-
dently associated with mortality.
Results. Mortality was 17% at 2 weeks and 34% at 10 weeks. Altered mental status (odds ratio [OR], 3.1; 95%
conﬁdence interval [CI], 1.7–5.9), high cerebrospinal ﬂuid (CSF) fungal burden (OR, 1.4 per log10 colony-forming
units/mL increase; 95% CI, 1.0–1.8), older age (>50 years; OR, 3.9; 95% CI, 1.4–11.1), high peripheral white blood
cell count (>10 × 109 cells/L; OR, 8.7; 95% CI, 2.5–30.2), ﬂuconazole-based induction treatment, and slow clearance
of CSF infection were independently associated with 2-week mortality. Low body weight, anemia (hemoglobin <7.5
g/dL), and low CSF opening pressure were independently associated with mortality at 10 weeks in addition to
altered mental status, high fungal burden, high peripheral white cell count, and older age.
In those followed for 1 year, overall mortality was 41%. Immune reconstitution inﬂammatory syndrome occurred
in 13% of patients and was associated with 2-week CSF fungal burden (P = .007), but not with time to initiation of
antiretroviral therapy (ART).
Conclusions. CSF fungal burden, altered mental status, and rate of clearance of infection predict acute mortality
in HIV-associated CM. The results suggest that earlier diagnosis, more rapidly fungicidal amphotericin-based regi-
mens, and prompt immune reconstitution with ART are priorities for improving outcomes.
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Human immunodeﬁciency virus (HIV)–associated cryptococ-
cal meningitis (CM) is the commonest cause of adult meningi-
tis in much of Africa [1–4]. Despite antifungal treatment, acute
mortality in the developing world remains between 24% and
43% [5–7], and CM accounts for 10%–20% of all HIV-related
deaths in sub-Saharan Africa [8]. The median time to death fol-
lowing hospital admission with CM is 10–13 days [6]. To
develop evidence-based interventions, it is essential to deter-
mine the key predictors of mortality. Using data from a cohort
of 501 patients with CM from Thailand, South Africa, Malawi,
and Uganda, we describe the presenting clinical features and
outcomes of patients with HIV-associated CM, and report the
results of a predictive model used to identify the clinical and
microbiological factors at baseline independently associated
with mortality. We provide an analysis of factors associated
with altered mental status, cerebrospinal ﬂuid (CSF) fungal
burden, CSF opening pressure (OP) at presentation, rate of
clearance of infection, and immune reconstitution inﬂammato-
ry syndrome (IRIS).
METHODS
The cohort comprised patients from 9 trials conducted from
2002 to 2010 at 5 sites (Table 1) in Thailand, South Africa,
Malawi, and Uganda. The trials have been reported elsewhere,
and represent all trials of HIV-associated CM published (at the
time of analysis) using early fungicidal activity (EFA) as the
primary outcome [5, 9–16]. A previous analysis of 262 patients
explored the correlation between rate of clearance of infection
and survival [17]. Combining the data from the constituent
trials into a combined cohort was done to obtain the power
needed to reliably determine the predictors of mortality in pa-
tients with HIV-associated CM. All trials were sponsored by St
George’s University of London and approved by the St
George’s Research Ethics Committee and local ethics commit-
tees.
Participants and Procedures
Following informed consent, HIV-positive adults with CM, di-
agnosed by cerebrospinal ﬂuid (CSF) India ink or cryptococcal
antigen testing (Meridian Cryptococcal Latex Agglutination
System, Meridian Bioscience) were enrolled consecutively. All
the trials had similar inclusion/exclusion criteria (Table 1). Pa-
tients already receiving antiretroviral therapy (ART) and those
with previous episodes of CM were excluded from this analysis.
Induction therapy differed by study as described previously [5,
9–16]. Following 2 weeks’ induction therapy, patients received
8 weeks of oral ﬂuconazole consolidation (400–800 mg/day)
then maintenance therapy (ﬂuconazole 200 mg/day). Routine
drug level monitoring was not performed. ART was started 2–6
weeks after starting antifungal therapy in accordance with local
protocols (ART was not routinely available during the earliest
trial [9]). Cohorts in Thailand, Uganda, and Malawi were fol-
lowed for 10 weeks, and those in South Africa for 12 months.
Evaluations and Outcomes
On study enrollment, detailed history and clinical examination
ﬁndings were recorded. Lumbar punctures with OP measure-
ments and quantitative CSF cultures were performed on days 1,
3, 7, and 14. Patients with a markedly elevated OP (>30 cm) or
symptoms of raised intracranial pressure had more frequent
lumbar punctures [18]. CSF cell count, protein, and glucose
levels were determined. CSF interferon gamma (IFN-γ), tumor
necrosis factor alpha (TNF-α), and interleukin 6 (IL-6) concen-
trations were measured in patients from the Thai and South
African sites using the Luminex multianalyte platform and Bio-
Rad cytokine kits [19]. Cryptococcal clearance was calculated
as the decrease in log colony-forming units (CFU) per milliliter
of CSF per day derived from the slope of the linear regression
of log CFU per milliliter against time for each patient [9]. Base-
line blood tests included hematology, renal and liver function,
CD4 cell counts, and, where available, plasma HIV load. The
primary outcome in all studies was rate of decrease in CSF
cryptococcal CFU (ie, EFA). Secondary outcomes included
mortality at 2 and 10 weeks. Cryptococcal meningitis IRIS
(CM-IRIS) was diagnosed according to uniform criteria [20].
In patients who died, the presumed cause of death was ascer-
tained by 2 study clinicians.
Statistical Analysis
Data were analyzed using Stata software, version 11 (Stata-
Corp). Variables were compared using Kruskal-Wallis, χ2, χ2
for trend, Fisher exact, or t tests. Relationships between contin-
uous variables were examined using the Pearson correlation
coefﬁcient or Spearman log-rank test. Multivariable logistic re-
gression models were constructed using stepwise regression
with the primary objective of determining the clinical and mi-
crobiological factors at baseline associated independently with
all-cause mortality (as measured at 2 and 10 weeks). A predic-
tive modeling strategy was used in which variables were select-
ed for model inclusion based upon (1) a priori knowledge from
previous studies (CD4 cell count), and (2) association with
outcome in univariable analysis. Variables associated with mor-
tality in univariable analysis (P ≤ .1) were included in the ﬁrst
ﬁt of the multivariable model and retained, based on likelihood
ratio testing, if they signiﬁcantly improved model ﬁt, to obtain
the most parsimonious model identifying predictors of mortali-
ty. Clustering by individual study was accounted for using a hi-
erarchical mixed effects model including a random-effects term
for “study.” An a priori decision was made to adjust the multi-
variable model for amphotericin (AmB) vs ﬂuconazole-based
treatment as a potential confounder in the relationship between
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baseline factors and outcomes. Exploring the effect of treatment
on outcome, after adjusting for other predictors, was a second-
ary objective. Patients with missing outcome data were cen-
sored from the main analysis, with sensitivity analyses
performed assuming that all patients lost were either dead or
alive. Further models were constructed to examine the baseline
factors associated with altered mental status, baseline fungal
burdens, and CSF opening pressure; to examine the impact of
Table 1. Component Studies Contributing to the Combined Cohort
Author and Type
of Studya Site and Year
No. of
Subjects Induction Treatmentb
ART
Available
EFA, log10 CFU/
mL/d, Mean (SD)
Brouwer et al [9]
RCT
Thailand 2002 64 AmB 0.7 mg/kg/d (n = 16) No −0.31 (0.18)
AmB 0.7 mg/kg/d + 5-FC 100 mg/kg/d (n = 16) −0.54 (0.19)
AmB 0.7 mg/kg/d + Fluc 400 mg/d (n = 16) −0.39 (0.15)
AmB 0.7 mg/kg + 5-FC 100 mg/kg + Fluc 400 mg/d
(n = 16) (All for 14 d)
−0.38 (0.13)
Bicanic et al [10]
Cohort study
South Africa
2005
54 AmB 1 mg/kg/d for 7 d then Fluc 400 mg/d (n = 49) Yes −0.48 (0.28)
Fluc 400 mg/d for 14 d (n = 5) −0.02 (0.05)
Bicanic et al [5]
RCT
South Africa
2005–2006
64 AmB 0.7 mg/kg/d + 5-FC 100 mg/kg/d (n = 30) Yes −0.45 (0.16)
AmB 1 mg/kg/d + 5-FC 100 mg/kg/d (n = 34) (Both
for 14 d)
−0.56 (0.24)
Longley et al [11]
Cohort study
Uganda 2005–
2007
60 Fluc 800 mg/d (n = 30) Yes −0.07 (0.17)
Fluc 1200 mg/d (n = 30) (Both for 14 d) −0.18 (0.11)
Nussbaum et al [12]
RCT
Malawi 2008 41 Fluc 1200 mg/d (n = 20) Yes −0.11 (0.10)
Fluc 1200 mg/d + 5-FC 100 mg/kg/d (n = 21) (Both
for 14 d)
−0.28 (0.17)
Loyse et al [13]
RCT
South Africa
2006–2008
80 AmB 1 mg/kg/d + 5-FC 100 mg/kg/d (n = 21) Yes −0.41 (0.22)
AmB 1 mg/kg/d + Fluc 800 mg/d (n = 22) −0.38 (0.18)
AmB 1 mg/kg/d + Fluc 1200 mg/d (n = 24) −0.41 (0.35)
AmB 1 mg/kg/d + Vori 600 mg/d (n = 13)
(All for 14 d)
−0.44 (0.20)
Muzoora et al [14]
Cohort study
Uganda 2008–
2009
30 AmB 1 mg/kg/d for 5 d + Fluc 1200 mg/d for 14 d
(n = 30)
Yes −0.3 (0.11)
Jackson et al [15]
RCT
Malawi 2009–
2010
40 AmB 1 mg/kg/d for 7 d + Fluc 1200 mg/d for 14 d
(n = 20)
Yes −0.39 (0.20)
AmB 1 mg/kg/d for 7 d + Fluc 1200 mg/d and 5-FC
100 mg/kg/d for 14 d (n = 20)
−0.49 (0.15)
Jarvis et al [16]
RCT
South Africa
2007–2010
90 AmB 1 mg/kg/d + 5-FC 100 mg/kg/d (n = 31) Yes −0.49 (0.15)
AmB 1 mg/kg/d + 5-FC 100 mg/kg/d + IFN-γ 100
µg days 1 & 3 (n = 29)
−0.64 (0.27)
AmB 1 mg/kg/d + 5-FC 100 mg/kg/d + IFN-γ 100
µg days 1, 3, 5, 8, 10, & 12 (n = 30) (AmB+ 5-FC
for 14 d in all arms)
−0.64 (0.22)
Abbreviations: 5-FC, 5-fluorocytosine; AmB, amphotericin B; ART, antiretroviral therapy; CFU, colony-forming units; EFA, early fungicidal activity; Fluc, fluconazole;
IFN, interferon; RCT, randomized controlled trial; SD, standard deviation; Vori, voriconazole.
a The 9 studies were conducted in 5 sites: Sappasitprasong Hospital, Ubon Ratchathani, Thailand; GF Jooste Hospital, Cape Town, and Edendale Hospital,
Pietermaritzburg, South Africa; Kamuzu Central Hospital/University of North Carolina Project, Lilongwe, Malawi; and Mbarara University Hospital, Uganda.
Exclusion criteria at all clinical trials were an alanine aminotransferase level >5 times the upper limit of normal (>200 IU/mL), neutrophil count <500 × 106 cells/L,
platelet count <50 000 × 106 cells/L, pregnancy, lactation, previous serious reaction to study drugs, or concomitant medication contraindicated with study drugs
(cisapride and the class of antihistamines including terfenadine and astemizole). Eight hundred ninety-six patients were screened for inclusion in the clinical trials;
523 met eligibility criteria. Reasons for exclusion were ART use in 162, inability to obtain consent in 65 (usually due to reduced Glasgow Coma Score), prior
cryptococcal meningitis in 36, patient refusal in 18, death prior to consent in 12, and other reasons including prior antifungal use and study exclusion criteria in 80.
b AmB was administered by intravenous infusion in all studies, and fluconazole by the oral or nasogastric route. Following 2 weeks of induction therapy, patients
received 8 weeks of oral fluconazole consolidation therapy (400–800 mg/d), then maintenance therapy (fluconazole 200 mg/d).
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ART timing and IRIS on longer-term outcomes; and to de-
scribe the relationship between EFA and outcome. EFA was
modeled both as a single linear term for each patient as pre-
viously described [17] and as a time-updated variable in a Cox
regression. In the group with 1 year of follow-up data, Kaplan-
Meier survival curves were compared using the Mantel-
Haenszel log-rank test.
RESULTS
Baseline Characteristics and Outcome
After screening 896 patients, 523 met eligibility criteria for in-
clusion in the clinical trials, consented to participation, and
were included. Of these, we studied the 501 ART-naive patients
with a ﬁrst episode of CM (Tables 1 and 2). The median age
was 34 years, and 52% were male. All had conﬁrmed HIV infec-
tion; 76% were known to be HIV positive at time of presenta-
tion, diagnosed a median of 152 days (interquartile range
[IQR], 44–745 days) earlier; the remainder tested HIV positive
at study enrollment. Male patients presented with a longer
median reported duration of symptoms than female patients
(14 vs 10 days; P = .004). The median CD4 count was 23 cells/
µL. Amphotericin B deoxycholate ([AmB] 0.7–1 mg/kg/day)
induction treatment was used in 80% of patients, and 20% re-
ceived ﬂuconazole-based induction (median, 1200 mg/day)
without AmB. All-cause mortality was 17% at 2 weeks and 34%
at 10 weeks (Tables 3 and 4). Of patients in care at 2 weeks (n =
410), 244 were started on ART a median of 30 days (IQR, 26–
42 days) after starting antifungal therapy. Nine patients were
lost to follow-up at 2 weeks, and 17 at 10 weeks.
Independent Associations With Outcome
Four variables independently predicted mortality at 2 weeks in
multivariable analysis: altered mental status, high baseline CSF
fungal burden (measured by either quantitative cryptococcal
culture [QCC] or cryptococcal antigen titer, which were closely
correlated; Supplementary Figure 1), older age, and high pe-
ripheral white blood cell count (Table 3). Patients with altered
mental status at presentation had a 3-fold increase in mortality
at 2 weeks; there was an incremental 1.4 odds increase in mor-
tality with each log10 CFU/mL increase in fungal burden; and
patients aged ≥50 years were almost 4 times more likely to die
than those aged <50 years.
Seven baseline parameters were associated independently with
10-week mortality: altered mental status, high baseline fungal
burden, older age, low body weight, low CSF opening pressure
(OP ≤25 cm CSF), high peripheral blood white cell count, and
anemia (Table 4). AmB treatment was associated independently
with lower mortality at both 2 and 10 weeks; however it should
be noted that ﬂuconazole-treated patients were predominantly
from the lowest-resource settings (97% Uganda or Malawi).
Altered Mental Status
At presentation, 25% of patients had altered mental status. In a
multivariable regression model including 409 patients with
complete data, the strongest predictor of altered mental status
Table 2. Baseline Characteristics of the Cohort
Characteristic Variable No.
% (No.) or Median
(IQR)
Demographics Age, y 499 34 (29–39)
Sex, male 501 52% (260)
History Concurrent
tuberculosis
419 25% (123)
Duration of
symptoms, d
458 14 (7–21)
Symptoms Headache 496 99% (489)
Febrile symptoms 497 57% (280)
Visual symptoms 493 51% (250)
Hearing loss 415 14% (60)
Seizures 496 19% (94)
Nausea/vomiting 494 54% (266)
Cough 494 35% (173)
Signs Fever, >37.5°C 479 23% (112)
Tachycardia, >100
bpm
491 19% (91)
Hypotension, <90/50
mmHg
485 3% (15)
Tachypnea, >20 bpm 463 19% (89)
Altered mental status 499 25% (123)
Meningism 492 75% (369)
Papilledema 311 12% (36)
Decreased visual
acuity, <6/6
361 39% (141)
Cranial nerve lesion 434 13% (57)
Investigations Raised OP >25 cm
CSF
450 51% (230)
Raised OP >30 cm
CSF
450 38% (173)
CSF white cell count,
×106/L
461 15 (1–57)
CSF protein, g/dL 392 0.7 (0.4–1.3)
CSF glucose, mg/dL 374 39.6 (25.2–50.5)
CSF CRAG, titera 247 1:1024 (1:512–4096)
QCC, log10 CFU/mL
a 496 5.30 (4.5–5.9)
CD4, cells/µL 456 24 (10–50)
Log10 VL, copies/mL 368 5.15 (4.7–5.5)
Outcomes 2-week mortality 492 17% (82)
10-week mortality 484 34% (163)
Time admission to
death, d
161 13 (5–310)
Abbreviations: CFU, colony-forming units; CRAG, cryptococcal antigen; CSF,
cerebrospinal fluid; IQR, interquartile range; OP, opening pressure; QCC,
quantitative cryptococcal culture; VL, HIV load.
a See Supplementary Figure 1 for a description of the relationship between
CSF CRAG and QCC.
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Table 3. Associations Between Baseline Variables and 2-Week Mortality
Variable Category No.
2-wk
Mortality
OR (95% CI),
Univariable
P
Value
AOR (95% CI),
Multivariablea,b
P
Value
Age <50 y 462 16% (73) 1 .009 1 .02
≥50 y 24 38% (9) 3.2 (1.3–7.8) 3.9 (1.4–11.1)
Sex Female 237 15% (36) 1 .5
Male 255 18% (46) 1.2 (.7–2.0)
Seizures No 397 14% (56) 1 .007
Yes 91 27% (25) 2.2 (1.2–3.9)
Mental status Normal 372 11% (39) 1 <.001 1 <.001
Abnormal 119 36% (43) 4.8 (2.9–8.0) 3.1 (1.7–5.9)
Weight <50 kg 175 17% (30) 1 .13
≥50 kg 282 10% (30) 0.7 (.4–1.1)
Pulse ≤100 bpm 395 15% (58) 1 .033
>100 bpm 88 24% (21) 1.9 (1.1–3.3)
Respiratory rate ≤20 bpm 368 13% (49) 1 .002
>20 bpm 87 26% (23) 2.6 (1.4–4.7)
CD4 cell count <25 cells/µL 229 17% (39) 1 .05 1 .07
25–49 cells/µL 106 8% (8) 0.4 (.2–.9) 0.4 (.2–.9)
50–99 cells/µL 74 7% (5) 0.4 (.1–.9) 0.5 (.2–1.4)
≥100 cells/µL 39 13% (5) 0.7 (.3–1.9) 1.1 (.4–3.2)
Hemoglobin ≥7.5 g/dL 429 15% (65) 1 .02
<7.5 g/dL 28 32% (9) 2.8 (1.2–6.7)
White blood cell count ≤10 × 109/L 382 14% (53) 1 <.001 1 .002
>10 × 109/L 21 48% (10) 6.7 (2.6–17.7) 8.7 (2.5–30.2)
CSF opening pressure ≤25 cm CSF 216 18% (38) 1 .488
>25 cm CSF 226 16% (37) 0.8 (.5–1.4)
CSF white cell count ≤20 × 106/L 272 20% (54) 1 .017
>20 × 106/L 183 11% (20) 0.5 (.3–0.9)
QCC 1st tertile 163 9% (15) 1 <.001 1.4 (1.0–1.8) .02
2nd tertile 162 14% (22) 1.5 (.8–3.1) (per log10
CFU/mL increase)c
3rd tertile 163 27% (44) 3.6 (1.9–6.8)
Treatment Fluconazole 99 26% (26) 1 .005 1 .05
Amphotericin 393 14% (56) 0.5 (.3–.8) 0.5 (.3–1.0)
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; CFU, colony-forming units; CSF, cerebrospinal fluid; OR, odds ratio; QCC, quantitative cryptococcal
culture.
ORs and 95% CIs for both univariable and multivariable associations are adjusted for clustering by study using a random-effects term for “study” in a hierarchical
mixed-effects logistic regression model. There was very little evidence for significant clustering by study in either the 2-week or 10-week model (likelihood-ratio test
of ρ= 0, P = .498 at both 2 and 10 weeks).
Numbers of patients included in each analysis are indicated in the table. A complete records analysis was performed rather than multiple imputation as there were
relatively few missing data points in the key exposure and outcome variables, and missing variables in important exposure variables such as CD4 cell count were
thought to be missing not at random, meaning imputation would not provide less biased results. It was suspected that lower values were associated with more
advanced disease and that blood tests were deferred in the sickest patients until they could consent to CD4 testing, meaning patients with the lowest values may
have been less likely to have a baseline test. A sensitivity analysis in which all patients lost to follow-up were assumed to be either alive or dead did not alter the
findings of either the 2 or 10-week model.
a Only variables included in the multivariable model are shown. Adjusted for treatment, CD4 count, age, mental status, and fungal burden (see footnote b). Number
included in final model = 445.
b Peripheral white cell count was significantly associated with 2-week mortality after adjustment, but was not included in the final model as observations were
missing for 90 patients. Its inclusion in a model considering only the patients with complete data (n = 370) did not alter the magnitude or significance of the
associations seen in the full model.
c QCC is shown in the univariable analysis as a categorical variable for ease of interpretation, but was included in the multivariable model as a continuous variable to
give a better fit.
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Table 4. Associations Between Baseline Variables and 10-Week Mortality
Variable Category No.
10-wk
Mortality
OR (95% CI),
Univariable
P
Value
AOR (95% CI),
Multivariablea,b
P
Value
Age <50 y 454 33% (148) 1 .014 1 .009
≥50 y 24 58% (14) 2.9 (1.2–6.8) 4.0 (1.4–11.4)
Sex Female 231 34% (79) 1 .815
Male 250 34% (84) 1.0 (.6–1.4)
Seizures No 389 33% (127) 1 .912
Yes 91 37% (34) 1.0 (.6–1.6)
Mental status Normal 366 25% (90) 1 <.001 1 <.001
Abnormal 117 62% (73) 5.2 (3.3–8.3) 2.8 (1.6–4.7)
Weight <50 kg 173 39% (68) 1 .003 1 .004
≥50 kg 277 25% (68) 0.5 (.3–.8) 0.6 (.4–1.0)
Pulse ≤100 bpm 389 31% (121) 1 .010
>100 bpm 86 45% (39) 1.9 (1.2–3.1)
Respiratory rate ≤20 bpm 363 30% (110) 1 .006
>20 bpm 84 45% (38) 2.0 (1.2–3.4)
CD4 cell count <25 cells/µL 226 35% (80) 1 .03c 1 .781
25–49 cells/µL 102 30% (30) 0.7 (.4–1.2) 0.8 (.5–1.4)
50–99 cells/µL 73 23% (17) 0.6 (.3–1.0) 0.8 (.4–1.5)
≥100 cells/µL 39 23% (9) 0.5 (.2–1.2) 0.7 (.3–1.9)
Hemoglobin ≥7.5 g/dL 423 31% (133) 1 .008 1 .02
<7.5 g/dL 27 56% (15) 3.0 (1.3–6.4) 3.0 (1.2–7.4)
White blood cell count ≤10 × 109/L 377 30% (114) 1 .001 1 .02
>10 × 109/L 21 63% (13) 4.7 (1.8–12.2) 4.0 (1.3–12.6)
CSF opening pressure ≤25 cm CSF 213 39% (83) 1 .009 1 .002
>25 cm CSF 223 30% (66) 0.6 (.4–.9) 0.4 (.3–.7)
CSF white cell count ≤20 × 106/L 268 35% (93) 1 .461
>20 × 106/L 179 31% (55) 0.9 (.6–1.3)
QCC 1st tertile 161 24% (38) 1 <.001 1.3 (1.1–1.7) .007
2nd tertile 161 32% (52) 1.5 (.9–2.4) (per log10
CFU/mL increase)d
3rd tertile 158 46% (72) 2.8 (1.7–4.5)
Treatment Fluconazole 99 53% (52) 1 <.001 1 .02
Amphotericin 385 29% (111) 0.4 (.2–.6) 0.5 (.3–.9)
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; CFU, colony-forming units; CSF, cerebrospinal fluid; OR, odds ratio; QCC, quantitative cryptococcal
culture.
ORs and 95% CIs for both univariable and multivariable associations are adjusted for clustering by study using a random-effects term for “study” in a hierarchical
mixed-effects logistic regression model. There was very little evidence for significant clustering by study in either the 2-week or 10-week model (likelihood-ratio test
of ρ= 0, P = .498 at both 2 and 10 weeks).
Numbers of patients included in each analysis are indicated in the table. A complete records analysis was performed rather than multiple imputation as there were
relatively few missing data points in the key exposure and outcome variables, and missing variables in important exposure variables such as CD4 cell count were
thought to be missing not at random, meaning imputation would not provide less biased results. It was suspected that lower values were associated with more
advanced disease, and that blood tests were deferred in the sickest patients until they could consent to CD4 testing, meaning patients with the lowest values may
have been less likely to have a baseline test. A sensitivity analysis in which all patients lost to follow-up were assumed to be either alive or dead did not alter the
findings of either the 2 or 10-week model.
a Only variables included in the multivariable model are shown. Adjusted for treatment, CD4 count, age, mental status, weight and fungal burden (see footnote b).
Number included in final model = 413.
b Peripheral white cell count, anemia, and raised CSF opening pressure were significantly associated with 10-week mortality after adjustment, but not included in
the final model to prevent missing observations, markedly limiting the size of the model. Inclusion in a model considering only the patients with complete data
(n = 391 for hemoglobin, n = 343 for peripheral white count, and n = 374 for raised CSF opening pressure) did not alter the magnitude or significance of the
associations seen in the full model.
c Test for trend.
d QCC is shown in the univariable analysis as a categorical variable for ease of interpretation, but was included in the multivariable model as a continuous variable to
give a better fit.
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was male sex (adjusted odds ratio [AOR], 2.2; 95% conﬁdence
interval [CI], 1.3–3.7; P = .003). Additional variables associated
independently with altered mental status were age >50 years
(AOR, 1.4; 95% CI, 1.1–2.0; P = .02) and very high CSF opening
pressure (>30 cm CSF; AOR, 1.8; 95% CI, 1.1–3.0; P = .02).
Altered mental status was not associated with any other vari-
ables examined including baseline fungal burden, CD4 count,
or CSF white cell count in adjusted analyses.
Baseline CSF Fungal Burden
CSF QCCs were negatively correlated with CD4 count, CSF white
cell count, CSF protein, and CSF proinﬂammatory cytokines (IL-
6, IFN-γ, and TNF-α). The strongest correlation was with CSF
IFN-γ (Pearson r =−0.4, P < .001; Figure 1). There was no signiﬁ-
cant correlation between QCC and CSFOP (Table 5).
CSF Opening Pressure
Raised baseline CSF OP (>25 cm CSF) was present in 51% of
the cohort (n = 230). Raised pressure was associated with papil-
ledema (OR, 2.6; 95% CI, 1.1–5.8; P = .02); however, other than
the association between very high CSF opening pressures (OP
>30 cm) and mental status described above, there were no
other signiﬁcant associations between high OP and clinical var-
iables. Raised OP correlated with increasing CSF TNF-α con-
centrations (Spearman r = 0.2, P = .008), but not with IFN-γ or
IL-6. Although there was no signiﬁcant correlation between
QCC and baseline CSF OP, high baseline QCC was necessary
but insufﬁcient for development of a high day 1 and day 14 OP
(Supplementary Figure 2).
Early Fungicidal Activity
EFA was associated with outcome, as shown previously among
a subset of 262 patients [17]. A slope measurement was avail-
able in 450 of the 501 patients, and in 129 of the 163 patients
who died. Mean EFA of those who died at 2 weeks was −0.24
(SD, 0.25) log10 CFU/mL/day vs −0.42 (SD, 0.25) log10 CFU/
mL/day in survivors (P < .001). In those who died at 10 weeks,
EFA was −0.34 (SD, 0.27) log10 CFU/mL/day vs −0.43 (SD,
0.24) log10 CFU/mL/day in survivors (P < .001). EFA remained
independently associated with mortality after adjusting for
altered mental status and fungal burden (mean difference in
EFA between survivors and fatal cases at 2 weeks, −0.15 log10
CFU/mL/day; 95% CI, .07−.22; P < .001). When the serial
counts were ﬁtted as a time-dependent variable, the adjusted
hazard ratio for death within the ﬁrst 2 weeks was 1.8 (95% CI,
Figure 1. Associations between cerebrospinal ﬂuid (CSF) interferon gamma (IFN-γ) concentrations and baseline fungal burden, rate of clearance of infection
(EFA), and 2-week mortality in the 243 Thai and South African patients with CSF cytokine measurements. CSF IFN-γ concentration was strongly associated
with rate of clearance of infection, with a 0.10 log10 CFU/mL/day (95% conﬁdence interval, .06–.15) increase in EFA for every log10 picogram increment in IFN-
γ concentration. Abbreviations: CFU, colony-forming units; EFA, early fungicidal activity; IFN, interferon; QCC, quantitative cryptococcal culture.
Table 5. Correlations Between Baseline Cerebrospinal Fluid
Fungal Burden, Derived From Quantitative Cryptococcal Culturesa
Correlation With QCCb No.
Correlation
Coefficient (r ) 95% CI
P
Value
CD4 cell count (cells/µL) 452 −0.24 −.33 to −.15 <.001
CSF opening pressure
(cm CSF)
446 0.05 −.05 to .14 .330
CSF white cell count
(×106/L)
458 −0.30 −.39 to −.21 <.001
CSF protein (g/dL) 389 −0.29 −.38 to −.19 <.001
CSF TNF-α (log10 pg/mL) 242 −0.20 −.32 to −.07 .002
CSF IL-6 (log10 pg/mL) 241 −0.15 −.27 to −.02 .024
CSF IFN-γ (log10 pg/mL) 243 −0.40 −.50 to −.29 <.001
Abbreviations: CI, confidence interval; CSF, cerebrospinal fluid; IFN, interferon;
IL-6, interleukin 6; QCC, quantitative cryptococcal culture; TNF, tumor necrosis
factor.
a Log10 colony-forming units per milliliter CSF.
bCorrelations were assessed using Spearman log-rank test for CD4 count, CSF
opening pressure, CSF white cell count, and CSF protein; and Pearson
correlation coefficient for TNF-α, IL-6, and IFN-γ, which were approximately
normally distributed when log transformed.
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1.2–2.5; P = .002) for each unit increase in the log10 CFU count.
The mean EFA was greater for amphotericin-based compared
with ﬂuconazole-based induction treatment (difference, 0.32
log10 CFU/day; 95% CI, .27–.36; P < .001). EFA was associated
independently with amphotericin-based treatment, baseline or-
ganism count, and CSF IFN-γ level (Figure 1).
Long-term Outcomes, ART Timing, and IRIS
Among the 266 patients enrolled in South Africa, survival analy-
sis was restricted to the 263 patients treated with AmB-based reg-
imens. The median age was 33 years (IQR, 29–39 years), 42% of
patients (n = 110) were male, median CD4 count was 28 cells/µL
(IQR, 12–57 cells/µL), and 15% had altered mental status. Of 179
patients surviving to 10 weeks and in care, median follow-up was
352 days (IQR, 209–409 days). Mortality was 13% at 2 weeks,
30% at 10 weeks, and 41% at the end of follow-up (Figure 2). Of
patients surviving to 2 weeks, 85% (n = 171) started ART a
median of 31 days (IQR, 23–46 days) after antifungal therapy.
IRIS developed in 13% (n = 22) of patients a median of 29 days
(IQR, 23–45 days) after starting ART, of whom 18% (n = 4) died.
IRIS was associated with day 14 CSF fungal burden (P = .007)
but not with time to ART (P = .4).
Presumed causes (as ascertained clinically by study physi-
cians) were recorded for 91% (98/108) of deaths (Figure 2).
Deaths during the initial 2 weeks were primarily attributed to
CM (85% [29/34]). Later deaths were mostly attributed to other
HIV-related infections or complications (67% [43/64]). Surviv-
al in patients who started ART was not associated with IRIS
(P = .3) or time to ART (P = .3) (Figure 2B).
DISCUSSION
This is the largest study examining factors determining
outcome in HIV-associated CM. The results emphasize the
high acute mortality in patients with CM, even among patients
primarily treated with amphotericin-based therapy in research
settings. Such patients are likely to have better outcomes than
those managed in routine care; hence, these results provide a
minimum mortality estimate. One-third of patients had died
by 10 weeks after presentation. However, the median time to
death of 13 days suggests that improved early interventions
could prevent some of these fatalities. Acute deaths were attrib-
uted mainly to CM. High fungal burden and slow clearance of
infection on treatment, together with altered mental status,
were the most important drivers of acute cryptococcal-related
mortality. After 2 weeks, other HIV-related causes of death pre-
dominated, and the risk factors for mortality in addition to
high fungal burden, slow clearance of infection, and altered
mental status, included older age, low CD4+ cell count, low
weight, and anemia, which have been identiﬁed previously as
predictors of mortality in HIV cohorts in general [21].
Figure 2. Kaplan-Meier survival curves. A, Survival in the 263 South
African amphotericin B (AmB)–treated patients followed up for 1 year. B,
Survival from enrollment in the subset of patients who started antiretrovi-
ral therapy (ART), stratiﬁed by ART timing (before and after the median of
31 days; P = .15). Only patients surviving to ART initiation are shown. C,
Cause of death data (as determined by study clinicians) in the cohort of
263 South African AmB-treated patients followed up for 1 year, split by
time from diagnosis. “Other” included tuberculosis (n = 11), bacterial
sepsis (n = 8), bacterial pneumonia (n = 7), nonspeciﬁed infections (n = 9),
Kaposi sarcoma (n = 2), lymphoma (n = 1), non–cryptococcal meningitis
immune reconstitution inﬂammatory syndrome (n = 3), ART toxicity (n = 2),
diarrhea/wasting syndrome (n = 4), and decompensation of chronic liver
disease (n = 1). Abbreviations: ART, antiretroviral therapy; CM, cryptococ-
cal meningitis; IRIS, immune reconstitution inﬂammatory syndrome.
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High baseline CSF fungal burden was one of the strongest risk
factors for mortality. It was associated with a low peripheral CD4
count, reﬂecting the importance of cell-mediated immunity in
controlling cryptococcal infection [22], and with a poor inﬂam-
matory response at the site of infection, as evidenced by low CSF
white cell counts and low levels of IFN-γ, TNF-α, and IL-6. The
rate of fungal clearance was independently related to outcome,
with slower clearance associated with higher mortality. This
strongly supports the use of EFA as a clinically relevant pharma-
codynamic endpoint for phase 2 clinical studies [17]. Higher
levels of proinﬂammatory CSF IFNγ were associated with more
rapid rates of fungal clearance during treatment [17, 19] and
lower fungal burdens at presentation, demonstrating the impor-
tance of IFN-γ in the protective immune response, and reinforc-
ing the rationale for augmentation of proinﬂammatory responses
with IFN-γ immunotherapy as a therapeutic approach [16].
Amphotericin-based treatments were more rapidly fungicidal
than ﬂuconazole-based treatments, and the mortality in ﬂucona-
zole-treated patients was almost double that in amphotericin B-
treated patients at 10 weeks. However the majority of ﬂucona-
zole-treated patients were from the lowest-resource settings, and
it is possible that the association between ﬂuconazole use and
mortality is confounded by factors relating to study site; however,
the association remained statistically robust after adjustment for
the other key variables associated with outcome, including abnor-
mal mental status and baseline fungal burden. The clear associa-
tion between slow rates of fungal clearance and poor outcomes
provides a strong argument in favor of rapidly fungicidal initial
treatments, andmorewidespread use of rapidly fungicidal ampho-
tericin B combination therapy is likely to reduce early mortality.
The pathophysiological basis of altered mental status, the
other main risk factor for mortality, remains unclear. The inde-
pendent associations of altered mental status with male sex and
older age have not been reported previously. High CSF opening
pressure (>30 cm) was associated independently with altered
mental status, but was not contributory to altered mental status
in the majority of cases; half of those with altered mental status
did not have markedly raised pressures. Of note, altered mental
status was not associated with CD4 count, CSF white cell
count, or fungal burden.
High CSF opening pressure was not associated with increased
mortality in this cohort, in contrast to earlier reports [23]. This
may have been a result of management: all patients routinely had
4 lumbar punctures over the ﬁrst 2 weeks of treatment, and raised
pressures were managed according to established guidelines [18].
A novel ﬁnding of this analysis was that raised CSF opening pres-
sures at baseline, in patients managed according to these guide-
lines, were associated with improved outcomes at 10 weeks. It is
possible that proinﬂammatory CSF cytokine responses (TNF-α
was associated with raised pressure) may be protective in situa-
tions where raised OP is appropriately managed, or that large
volume CSF drainage is beneﬁcial over and above its role in re-
ducing pressure [23]. These ﬁndings emphasize the importance
of CSF pressure management in patients with CM, and highlight
the need for widened access to manometers to manage pressure
safely in centers in Africa with the highest burden of disease.
Long-term survival in the cohort of South African patients
with access to AmB and ART was good, provided patients sur-
vived the acute period. ART was usually started between 3 and
6 weeks after antifungal therapy. Within this time frame, there
was no association between earlier ART initiation and the de-
velopment of subsequent IRIS. Patients who developed IRIS
did not have higher overall mortality. The majority of deaths
after 2 weeks were attributed to other HIV-related illnesses that
may have been preventable through earlier initiation of ART. In
the context of amphotericin induction, ART initiation nearer
to 3 rather than 6 weeks after starting antifungal therapy may
prevent some of the later HIV-related mortality, while not sub-
stantially increasing the risk of IRIS.
A potential limitation of this analysis, derived from multiple
cohorts, is possible residual confounding due to unmeasured
study speciﬁc effects, relating to temporal or geographic differ-
ences between studies. However a key strength of this cohort is
the extensive prospectively collected baseline data, allowing ad-
justment to minimize confounding. There was little evidence of
clustering by study within the hierarchical model, and the robust-
ness of the key conclusions was further supported by consistency
across univariable and multivariable analyses, and the sensitivity
analyses performed. Levels of missing data among outcomes and
the key predictor variables were low, reducing the risk of bias.
In summary, these data provide a rationale for several strate-
gies to improve outcomes. First, earlier diagnosis of CM should
be possible, resulting in lower fungal loads at presentation and
a reduction in mortality. Clinicians should have a low threshold
for lumbar puncture in HIV-positive patients presenting with
headache. Novel point-of-care antigen tests [24, 25] should now
facilitate earlier diagnosis. Given the high proportion of pa-
tients presenting with CM who have already been diagnosed
with HIV (76%), screening for subclinical infection with point-
of-care antigen tests and preemptive antifungal treatment,
along with early ART initiation, could prevent a substantial
proportion of clinical disease from developing [26–28]. Second,
increasing access to the most fungicidal AmB-based regimens
is a priority in settings with a high incidence of CM [29–31], in
particular sub-Saharan Africa. Last, prompt initiation of ART
is required to address the substantial proportion of deaths in
these patients that are HIV but not CM related.
Supplementary Data
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